Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06597721 · ClinicalTrials.gov registry record · Phase 1
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
A Phase 1 study of Advanced Solid Tumor, sponsored by Adcendo ApS.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 210
- Enrollment target
- 10
- Study locations
NCT06597721: Recruiting Phase 1 study of Advanced Solid Tumor, sponsored by Adcendo ApS.
NCT06597721 is a Phase 1 study of Advanced Solid Tumor that is actively recruiting participants, run by Adcendo ApS. The registered enrollment target is 210 participants, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target. The trial reports 10 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06597721, a Phase 1 study of Advanced Solid Tumor, is actively recruiting participants, sponsored by Adcendo ApS.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 210 participants
- Enrollment target
- 10
- Study locations
Study Summary
Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for advanced solid tumors. The main purpose of the study is to determine the Maximum Tolerated Dose (MTD), the recommended dose and the safety and tolerability of ADCE-T02 when given as a single therapy over a range of different dose levels.
Primary Outcome
The MTD will be determined using DLTs
Conditions Studied
Interventions
- DRUG ADCE-T02
Study Locations (10)
Texas
- MD Anderson Cancer Center - Houston
- START San Antonio - San Antonio
Victoria
- Peninsula and South Eastern Haematology and Oncology Group (PSEHOG) - Frankston
- Cabrini Hospital - Malvern
Arkansas
- Highlands Oncology Group - Rogers
Connecticut
- Yale University Cancer Center - New Haven
Massachusetts
- Massachusetts General Hospital - Boston
New South Wales
- Scientia Clinical Research - Randwick
South Australia
- Southern Oncology Clinical Research Unit - Bedford Park
Western Australia
- Linear Clinical Research - Nedlands
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2024-11-25 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 1 |
What NCT06597721 shows while recruiting
NCT06597721 is an interventional study that assigns participants to a tested intervention. The registered 210 participants enrollment target is mid-sized for trials with a published cap, roughly in line with the 192-participant average among 189 other Advanced Solid Tumor trials with a reported enrollment target.
The record links to 1 condition, with Advanced Solid Tumor appearing as the primary indexed condition, and to 1 intervention - of which ADCE-T02 is the first listed.
NCT06597721 lists 10 locations in 8 states (Texas, Victoria, Arkansas).
Frequently Asked Questions
What is clinical trial NCT06597721 about?
NCT06597721 is a clinical study titled "ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours". Adcendo ApS is conducting a phase 1 study of an investigational drug called ADCE-T02 (previously known as AMT-754), a tissue factor targeted antibody-drug conjugate which may be used in the future as a possible treatment for advanced solid tumors. The main purpose of the study is to determine the M...
What is the current status of trial NCT06597721?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 210 participants. The study started on 2024-11-25. Estimated completion is 2026-12-31.
What conditions does trial NCT06597721 study?
This clinical trial studies the following conditions: Advanced Solid Tumor.
What interventions are being tested in trial NCT06597721?
The interventions under investigation include: ADCE-T02 (DRUG).
Who is sponsoring clinical trial NCT06597721?
This trial is sponsored by Adcendo ApS, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06597721 being conducted?
This trial has 10 study locations across Arkansas, Connecticut, Massachusetts, Texas, New South Wales. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06597721's enrollment target sits among peer trials
210 61st of 189 higher than 128 of 189 other Advanced Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
PM14 Administered Intravenously to Patients with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of EP0031 in Patients With Advanced RET-altered Malignancies
RECRUITING · Phase 1
-
Study of AVZO-021 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02665923 · 210 participants
Gastric Emptying in Neonates and Infants After Formula Feeding
- NCT03322891 · 210 participants · NA
Improving Health Literacy in African-American Prostate Cancer Patients
- NCT03544489 · 210 participants · Phase 2
Effectiveness of Exercise After an ICD
- NCT04408430 · 210 participants · NA
The MITRAL II Pivotal Trial (Mitral Implantation of TRAnscatheter vaLves).
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI